Tests cholesterol-lowering care started in emergency department patients
Tests whether starting a statin and lifestyle advice in emergency patients lowers cholesterol.
Key facts
- Who runs it
- Wake Forest University Health Sciences
- Where
- Winston-Salem, United StatesSee the site
- Trial code
- Registry title
- Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 130 people, planned
- Started
- 5 Aug 2024
- Expected to end
- 31 Mar 2029
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Statin (rosuvastatin 10 or 40 mg daily, depending on risk)
- Healthy Lifestyle Counseling
- Outpatient Followup
- Record updated
- 27 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 40-75 being checked in the emergency department for a possible heart attack, who have raised heart-disease risk, diabetes or known heart or blood vessel disease and are not yet on cholesterol medicine.
- Age
- 40-75 years
- Sex
- All sexes can join.
- Disease stage
- Being checked for acute coronary syndrome, with a 10-year ASCVD risk of 7.5% or more, or known diabetes, or known ASCVD (heart attack, unstable angina, stent, bypass, stroke, mini-stroke or peripheral artery disease).
- Earlier treatment
- People already on a cholesterol-lowering medicine (such as a statin, PCSK9 inhibitor, bempedoic acid, ezetimibe or inclisiran) cannot join.
- Biomarker or test result
- High-sensitivity troponin I below 100 ng/L.
Main reasons for not taking part
- ST-elevation heart attack alert, or ST depression over 1 mm in neighbouring leads
- Already taking a cholesterol-lowering medicine, or statin intolerance
- Unstable vital signs, or high-sensitivity troponin I of 100 ng/L or more
- End-stage kidney disease or GFR below 30, or liver cirrhosis
- Pregnancy, expected hospital stay, or life expectancy under 1 year
The registry criteria, word for word
Show all 25 criteriaShow less
Who can take part
- Evaluation for Acute Coronary Syndrome
- Age 40-75 Years
- 10-year Atherosclerotic Cardiovascular Disease (ASCVD) Risk ≥7.5% or Known Diabetes or; Known ASCVD:
- Myocardial Infarction
- Unstable Angina
- Percutaneous Coronary Intervention
- Coronary Artery Bypass Graft
- Stroke
- Transient Ischemic Attack
- Peripheral Artery Disease
Who cannot take part
- On a Lipid Lowering Agent (Statin, PCSK9 Inhibitor, Bempedoic Acid, Ezetimibe, Inclisiran, etc.)
- ST-Segment Elevation Myocardial Infarction (STEMI) Activation
- End-stage renal disease (ESRD) and/or glomerular filtration rate (GFR) <30 mL/min/1.73 m2
- ST Depression >1 mm in Contiguous Leads
- Inability to Return for 30-day Follow-up
- Unstable Vitals (Systolic blood pressure <90, HR >120 or <50, oxygen saturation <90%)
- Statin Intolerance
- Any Resulted High-Sensitivity Troponin I ≥100 ng/L
- Liver Cirrhosis
- Pregnancy
- Anticipated Hospitalization
- Life Expectancy <1 Year
- Transfer from Another Hospital
- Prisoner
- Non-English Speaking
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 75 years old?
Where in United States
- Wake Forest University Health SciencesWinston-Salem, United StatesContact: Lauren KoehlerTaking people
About the trial
What the trial wants to find out
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American Heart Association and US Preventive Services Task Force guidelines designed to initiate preventive cardiovascular care for emergency department patients being evaluated for acute coronary syndrome. The overarching goals of this proposal are to (1) determine the efficacy of EMERALD at lowering low-density lipoprotein cholesterol (LDL-C) and non high-density lipoprotein cholesterol (non-HDL-C) among at-risk Emergency Department (ED) patients who are not already receiving guideline-directed outpatient preventive care and (2) inform our understanding of patient adherence and determinants of implementation for ED-based cardiovascular disease prevention strategies.
The 2 groups in the trial
- Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) armTreatment being tested
In the EMERALD arm, care will vary by risk level: (1) patients with known atherosclerotic cardiovascular disease (ASCVD) will qualify for a high-intensity statin (rosuvastatin 40 mg daily) and referral to cardiology for secondary prevention, (2) patients with low-density lipoprotein cholesterol (LDL-C) ≥190 mg/dL will receive a high-intensity statin and a cardiology referral for primary prevention, and (3) for the remaining patients, Emergency Department providers will calculate 10-year ASCVD risk using the Pooled Cohort Equations. These patients will be categorized as (3A) high risk patients (10-year risk ≥20%) who will receive a high-intensity statin and a cardiology referral and (3B) moderate risk patients (10-year risk ≥7.5% but \<20% or those with known diabetes and 10-year risk \<20%) who will receive a moderate-intensity statin (rosuvastatin 10 mg daily) and a primary care referral. EMERALD patients will also receive healthy lifestyle counseling.
Treatment: Statin (rosuvastatin 10 or 40 mg daily, depending on risk), Healthy Lifestyle Counseling, and Outpatient Followup
- Usual Care ArmExisting treatment, for comparison
Patients in the usual care arm will receive the current standard of care, which consists of primary care referral and no Emergency Department statin prescription. They will also receive healthy lifestyle counseling.
Treatment: Healthy Lifestyle Counseling and Outpatient Followup
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Initiating Preventive Care for Hyperlipidemia in the Emergency Department: The EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders) Trial
- Plain-language title
- Tests cholesterol-lowering care started in emergency department patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06488105, who can take part
- Record updated
- 27 February 2026